For localized information and support, would you like to switch to your country-specific website for {0}?
cobas® liat SARS-CoV-2 & Influenza A/B v2
nucleic acid test
IVD
For in vitro diagnostic use.
Reduce misdiagnosis with a fast, reliable, and actionable test
Respiratory viruses often cause similar symptoms but may require distinct patient management approaches. SARS-CoV-2 (COVID-19) and influenza are particularly prone to causing severe illness, and misdiagnosis can lead to health complications or community spread.1 While anyone can contract a respiratory virus, higher-risk groups, such as the elderly, young children, and the immunocompromised, are especially vulnerable.2 Therefore, effective tools are essential to provide rapid results, enabling early and effective patient care in time-sensitive clinical situations such as emergency care settings.
The cobas® liat SARS-CoV-2 & Influenza A/B v2 is an automated rapid multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) test that detects SARS-CoV-2 and Influenza A/B in just 20 minutes from a nasal or nasopharyngeal swab sample.3 These rapid test results can guide clinical decisions on patient treatment and isolation precautions for effective infection control. With the reliable and prompt performance of the cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test, healthcare providers on the front line can swiftly obtain the critical information needed to effectively rule in or rule out these infections and efficiently manage patients.
What’s new in version 2?
As viruses continue to evolve, so too must our diagnostic tools. Version 2 of the cobas liat SARS-CoV-2 & Influenza A/B assay builds on the trusted performance of version 1 but with key improvements.4
- Improved inclusivity for all targets with updated primers and probes predicted by in silico analysis to detect most recent sequences from SARS-CoV-2 and influenza A/B infections in humans
- Flu A detection: Retains the well-conserved matrix gene target, now with an additional primer to improve inclusivity
- Flu B detection: Features a newly selected target—nonstructural protein 1 gene—to improve inclusivity
cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test clinical performance
View Full Tablecobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test clinical performance
| Nasopharyngeal swab* | Nasal swab* | ||||
|---|---|---|---|---|---|
PPA (95% CI) |
NPA (95% CI) |
PPA (95% CI) |
NPA (95% CI) |
LoD** (TCID50/mL) |
|
SARS-CoV-2 |
94.5% (90.7-96.8) |
97.6% (96.7-98.3) |
96.7% (93.4-98.4) |
97.2% (96.2-97.9) |
0.0350 |
Influenza A |
100% (93.4-100.0) |
99.3% (98.8-99.6) |
100% (93.2-100.0) |
99.3% (98.8-99.6) |
0.00325-0.295 |
Influenza B |
100% (85.1-100.0) |
99.3% (98.8-99.6) |
100% (86.2-100.0) |
99.5% (99.0-99.7) |
0.183-0.979 |
**Strain references: SARS-CoV-2: USA-WA1/2020; Influenza A: Darwin/6/2021, Brisbane/02/2018; Influenza B: Austria/1359417/2021, Phuket/3073/2013
cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test specifications
View Full Tablecobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid test specifications
Instrument |
cobas® liat system |
Targets |
SARS-CoV-2, Influenza A, Influenza B |
Sample type |
Nasopharyngeal (NPS) and nasal swabs (NS) |
Collection media |
VTM, UTM and Saline |
Sample extraction |
Fully automated and integrated |
Technology |
Real-time RT-PCR |
Control |
Internal sample processing control, positive and negative controls |
Time to result |
~20 min |
Reagents |
Ready-to-use, pre-packed tube format |
Kit Storage |
2-8°C |
Registration |
IVDR and 510(k)/ CLIA-waived |
Use left and right arrow keys to scroll between the tabs
Overview
Technical Documents
Access important product documentation including relevant certificates and other resources.
After clicking below, you will be redirected to eLabDoc, where you can select your local country-specific documents.
Related products
References
- Bray L et al. Misdiagnoses in the Context of Suspected Pandemic Influenza or Coronavirus Disease 2019: A Systematic Review. Open Forum Infect Dis. 2022;9(11):ofac515.
- CDC Respiratory Illnesses. [Internet; cited 2025 March] Available from: https://www.cdc.gov/respiratory-viruses/risk-factors/index.html
- F. Hoffmann-La Roche Ltd. Data on file. cobas® liat SARS-CoV-2 & Influenza A/B CE-IVD Instructions for Use 10162546001-01EN
- F. Hoffmann-La Roche Ltd. Data on file. Improved Inclusivity and Target Coverage in CFRA Compared to FRTA and SCFA Assays for SARS-CoV-2, Flu A/B, and RSV.